Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    port delivery system | diabetic retinopathy
Previous Study | Return to List | Next Study

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04503551
Recruitment Status : Recruiting
First Posted : August 7, 2020
Last Update Posted : August 30, 2021
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Tracking Information
First Submitted Date  ICMJE August 5, 2020
First Posted Date  ICMJE August 7, 2020
Last Update Posted Date August 30, 2021
Actual Study Start Date  ICMJE August 10, 2020
Estimated Primary Completion Date January 18, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 5, 2020)
Percentage of participants with a ≥2-step improvement from baseline on the ETDRS-DRSS at Week 52 [ Time Frame: Week 52 ]
ETDRS = Early Treatment Diabetic Retinopathy Study DRSS = Diabetic Retinopathy Severity Scale The ETDRS-DRSS includes 13 score levels, ranging from the absence of retinopathy to PDR, including neovascularization and/or vitreous/preretinal hemorrhage.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 21, 2021)
  • Rate of participants developing a vision-threatening complication (defined as PDR, ASNV, or CI-DME [defined as central foveal thickness [CST] ≥325 μm on spectral-domain optical coherence tomography [SD-OCT]) through Week 52 [ Time Frame: From baseline through 52 weeks ]
    PDR = proliferative diabetic retinopathy ASNV = Anterior segment neovascularization
  • Rate of participants developing PDR or ASNV through Week 52 [ Time Frame: From baseline through 52 weeks ]
  • Rate of participants developing CI-DME through Week 52 [ Time Frame: From baseline through 52 weeks ]
  • Rate of participants developing a ≥ 2-step worsening from baseline on the ETDRS-DRSS through Week 52 [ Time Frame: From baseline through 52 weeks ]
  • Percentage of participants with a ≥ 3-step improvement from baseline on the ETDRS-DRSS at Week 52 [ Time Frame: Week 52 ]
  • Percentage of participants with a ≥ 3-step worsening from baseline on the ETDRS-DRSS at Week 52 [ Time Frame: Week 52 ]
  • Percentage of participants with a ≥ 2-step improvement from baseline on the ETDRS-DRSS over time [ Time Frame: Baseline up to Week 112 ]
  • Percentage of participants with a ≥ 3-step improvement from baseline on the ETDRS-DRSS over time [ Time Frame: Baseline up to Week 112 ]
  • Time to first development of either PDR, ASNV, or CI-DME [ Time Frame: Baseline up to Week 112 ]
  • Time to first development of PDR or ASNV [ Time Frame: Baseline up to Week 112 ]
  • Time to first development of CI-DME [ Time Frame: Baseline up to Week 112 ]
  • Time to first development of a ≥ 2-step worsening from baseline on the ETDRS-DRSS [ Time Frame: Baseline up to Week 112 ]
  • Time to first development of a ≥ 3-step worsening from baseline on the ETDRS-DRSS [ Time Frame: Baseline up to Week 112 ]
  • Change from baseline in Best-Corrected Visual Acuity (BCVA) as measured on the ETDRS chart over time [ Time Frame: Baseline up to Week 112 ]
    A vision score of 20/20 vision is considered normal. A score of 20/200 is considered being legally blind.
  • Percentage of participants who lose <15, < 10 and < 5 letters in BCVA from baseline over time [ Time Frame: Baseline up to Week 112 ]
  • Percentage of participants with a BCVA score of 69 letters (20/40 approximate Snellen equivalent) or better over time [ Time Frame: Baseline up to Week 112 ]
  • Change from baseline in CST as measured on SD-OCT over time [ Time Frame: Baseline up to Week 112 ]
  • Change from baseline in total macular volume as measured on SD-OCT over time [ Time Frame: Baseline up to Week 112 ]
  • Incidence and severity of ocular adverse events [ Time Frame: Baseline up to Week 112 ]
  • Incidence and severity of non-ocular adverse events [ Time Frame: Baseline up to Week 112 ]
  • Incidence, severity, and duration of adverse events of special interest [ Time Frame: Baseline up to Week 112 ]
  • Incidence, severity, and duration of ocular adverse events of special interest during the postoperative period (≤ 37 days after initial implant insertion) and follow-up period (> 37 days after implant insertion surgery) [ Time Frame: Baseline up to Week 112 ]
  • Serum concentration of ranibizumab observed over time [ Time Frame: Baseline up to Week 112 ]
  • Pharmacokinetic (PK) parameter value area under the concentration- time curve [ Time Frame: Baseline up to Week 112 ]
  • PK Parameter minimum serum concentration (Cmin) [ Time Frame: Baseline up to Week 112 ]
  • PK parameter half-life (t1/2) after PDS implant insertion [ Time Frame: Baseline up to Week 112 ]
  • Prevalence of anti-drug antibodies (ADAs) prior to study treatment and incidence of ADAs after study treatment [ Time Frame: Baseline up to Week 112 ]
  • Percentage of participants who do not undergo supplemental treatment with intravitreal ranibizumab within each refill-exchange interval [ Time Frame: Baseline up to Week 112 ]
  • Percentage of participants with adverse device effects [ Time Frame: Baseline up to Week 112 ]
  • Percentage of participants with serious adverse device effects [ Time Frame: Baseline up to Week 112 ]
Original Secondary Outcome Measures  ICMJE
 (submitted: August 5, 2020)
  • Rate of participants developing a vision-threatening complication (defined as PDR, ASNV, or CI-DME [defined as central foveal thickness [CST] ≥325 μm on spectral-domain optical coherence tomography [SD-OCT]) through Week 52 [ Time Frame: From baseline through 52 weeks ]
    PDR = proliferative diabetic retinopathy ASNV = Anterior segment neovascularization
  • Rate of participants developing PDR or ASNV through Week 52 [ Time Frame: From baseline through 52 weeks ]
  • Rate of participants developing CI-DME through Week 52 [ Time Frame: From baseline through 52 weeks ]
  • Rate of participants developing a ≥ 2-step worsening from baseline on the ETDRS-DRSS through Week 52 [ Time Frame: From baseline through 52 weeks ]
  • Percentage of participants with a ≥ 3-step improvement from baseline on the ETDRS-DRSS at Week 52 [ Time Frame: Week 52 ]
  • Percentage of participants with a ≥ 3-step worsening from baseline on the ETDRS-DRSS at Week 52 [ Time Frame: Week 52 ]
  • Percentage of participants with a ≥ 2-step improvement from baseline on the ETDRS-DRSS over time [ Time Frame: Baseline up to Week 112 ]
  • Percentage of participants with a ≥ 3-step improvement from baseline on the ETDRS-DRSS over time [ Time Frame: Baseline up to Week 112 ]
  • Time to first development of either PDR, ASNV, or CI-DME [ Time Frame: Baseline up to Week 112 ]
  • Time to first development of PDR or ASNV [ Time Frame: Baseline up to Week 112 ]
  • Time to first development of CI-DME [ Time Frame: Baseline up to Week 112 ]
  • Time to first development of a ≥ 2-step worsening from baseline on the ETDRS-DRSS [ Time Frame: Baseline up to Week 112 ]
  • Time to first development of a ≥ 3-step worsening from baseline on the ETDRS-DRSS [ Time Frame: Baseline up to Week 112 ]
  • Change from baseline in Best-Corrected Visual Acuity (BCVA) as measured on the ETDRS chart over time [ Time Frame: Baseline up to Week 112 ]
    A vision score of 20/20 vision is considered normal. A score of 20/200 is considered being legally blind.
  • Percentage of participants who lose < 10 and < 5 letters in BCVA from baseline over time [ Time Frame: Baseline up to Week 112 ]
  • Percentage of participants with a BCVA score of 69 letters (20/40 approximate Snellen equivalent) or better over time [ Time Frame: Baseline up to Week 112 ]
  • Change from baseline in CST as measured on SD-OCT over time [ Time Frame: Baseline up to Week 112 ]
  • Change from baseline in total macular volume as measured on SD-OCT over time [ Time Frame: Baseline up to Week 112 ]
  • Incidence and severity of ocular adverse events [ Time Frame: Baseline up to Week 112 ]
  • Incidence and severity of non-ocular adverse events [ Time Frame: Baseline up to Week 112 ]
  • Incidence, severity, and duration of adverse events of special interest [ Time Frame: Baseline up to Week 112 ]
  • Incidence, severity, and duration of ocular adverse events of special interest during the postoperative period (≤ 37 days after initial implant insertion) and follow-up period (> 37 days after implant insertion surgery) [ Time Frame: Baseline up to Week 112 ]
  • Serum concentration of ranibizumab observed over time [ Time Frame: Baseline up to Week 112 ]
  • Pharmacokinetic (PK) parameter value area under the concentration- time curve [ Time Frame: Baseline up to Week 112 ]
  • PK Parameter minimum serum concentration (Cmin) [ Time Frame: Baseline up to Week 112 ]
  • PK parameter half-life (t1/2) after PDS implant insertion [ Time Frame: Baseline up to Week 112 ]
  • Prevalence of anti-drug antibodies (ADAs) prior to study treatment and incidence of ADAs after study treatment [ Time Frame: Baseline up to Week 112 ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
Official Title  ICMJE A Phase III, Multicenter, Randomized Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy
Brief Summary Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator Arm
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description:
The visual acuity examiner will only conduct refraction and visual acuity assessments and will be masked, as best as possible, to the following items: study eye assignment; study visit type; and treatment assignment.
Primary Purpose: Treatment
Condition  ICMJE Diabetic Retinopathy
Intervention  ICMJE
  • Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
    Will be administered as per the schedule described in individual arm.
  • Drug: Intravitreal Ranibizumab 0.5 mg Injection
    Will be administered as per the schedule described in individual arm.
Study Arms  ICMJE
  • Experimental: PDS Arm
    Participants randomized to the PDS arm will receive two intravitreal ranibizumab injections and will then have the PDS implant (pre-filled with ranibizumab) surgically inserted. PDS implant refill-exchange procedures will be performed on a fixed interval every 36-weeks (Q36W) thereafter
    Interventions:
    • Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
    • Drug: Intravitreal Ranibizumab 0.5 mg Injection
  • Comparator Arm
    Participants randomized to the comparator arm will undergo study visits every 4 weeks (Q4W) for comprehensive clinical monitoring until they receive the PDS implant (pre-filled with ranibizumab). PDS implant refill-exchange procedures will be performed on a fixed interval Q36W thereafter. Participants will be eligible to receive intravitreal ranibizumab 0.5 mg injections if treatment eligibility criteria are met.
    Interventions:
    • Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
    • Drug: Intravitreal Ranibizumab 0.5 mg Injection
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: August 5, 2020)
160
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE January 18, 2023
Estimated Primary Completion Date January 18, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age ≥18 years at time of signing Informed Consent Form
  • Documented diagnosis of diabetes mellitus (Type 1 or Type 2)
  • HbA1c level of ≤12% within 2 months prior to screening or at screening

Inclusion Criteria for Study Eye

  • Moderately severe or severe NPDR (ETDRS-DRSS level 47 or 53)
  • BCVA score of ≥ 69 letters (20/40 approximate Snellen equivalent or better)

Exclusion Criteria:

  • Uncontrolled blood pressure
  • Cerebrovascular accident or myocardial infarction within 6 months prior to randomization
  • Atrial fibrillation diagnosis or worsening within 6 months prior to randomization
  • Current systemic treatment for a confirmed active systemic infection
  • Renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis, or anticipated to require hemodialysis or peritoneal dialysis at any time during the study
  • History of other disease, other non-diabetic metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of ranibizumab or surgical placement of the PDS implant; that might affect interpretation of the results of the study; or that renders the patient at high risk for treatment complications in the opinion of the investigator or Sponsor

Ocular Exclusion Criteria for Study Eye:

  • Presence of center-involved diabetic macular edema (defined as CST ≥325 µm)
  • Any intravitreal anti-VEGF treatment at any time prior to randomization
  • Any use of medicated intraocular implants, including Ozurdex® or Iluvien® implants at any time prior to randomization
  • Any intravitreal corticosteroid treatment at any time prior to randomization
  • Any periocular (e.g., subtenon) corticosteroid treatment at any time prior to randomization
  • Any PRP at any time prior to randomization
  • Any macular laser photocoagulation (such as micropulse and focal or grid laser) at any time prior to randomization
  • Active intraocular inflammation (grade trace or above)
  • Clinically significant abnormalities of the vitreous-retinal interface involving the macular area or disrupting the macular architecture, such as vitreous-retinal traction or epiretinal membrane (assessed by the investigator and confirmed by the central reading center)
  • Uncontrolled ocular hypertension or glaucoma and any such condition the investigator determines may require a glaucoma-filtering surgery during a participant's participation in the study
  • History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery
  • Any concurrent ocular condition (e.g., cataract, epiretinal membrane) that would require surgical intervention during the study to prevent or treat visual loss that might result from that condition
  • Any concurrent ocular condition (e.g., amblyopia, strabismus) that may affect interpretation of study results
  • History of other ocular diseases that gives reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab, that might affect interpretation of study results, or that renders the participant at high risk for treatment complications

Ocular Exclusion Criteria for Either Eye

  • Suspected or active ocular or periocular infection of either eye
  • Any history uveitis including idiopathic, drug-associated or autoimmune-associated uveitis
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Reference Study ID Number: GR41675 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. global.rochegenentechtrials@roche.com
Listed Location Countries  ICMJE Puerto Rico,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04503551
Other Study ID Numbers  ICMJE GR41675
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here ( https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Responsible Party Hoffmann-La Roche
Study Sponsor  ICMJE Hoffmann-La Roche
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Clinical Trials Hoffmann-La Roche
PRS Account Hoffmann-La Roche
Verification Date August 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP